High SABA Use: A Sign of the Uncontrolled Asthma Patient?
Short-acting beta agonists have been a first-line treatment for asthma for over 50 years.1 However, a growing body of evidence including data from the National Review of Asthma Deaths (NRAD) has shown that SABA overuse, defined as 3 or more canisters per year,1 is linked with a higher risk of exacerbations, which are associated with increased risk of mortality.2
The SABINA (SABA use IN Asthma) programme aims to understand whether high SABA use is a global problem and whether this occurs in patients with asthma across all severity levels.3 In this talk, Professor Jenni Quint discusses data from the global SABINA study, covering the different phases of this extensive programme including SABINA I, SABINA II and SABINA III and thus, contextualising the use of SABA in the UK with that observed internationally.
Professor Jenni Quint also discusses how high SABA use can impact the environment and the availability of a range of devices that would best suit different patients and help achieve improved sustainability.
1. National Institude for Healthcare and Excellence guidelines. November 2017. Available at: https://www.nice.org.uk/guidance/ng80/chapter/Recommendations#principles-of-pharmacological-treatment [Last accessed December 2021].
2. Royal College of Physicians. National Review of Asthma Deaths report. May 2014. Available at: https://www.rcplondon.ac.uk/projects/outputs/why-asthma-still-kills [Last accessed December 2021].
3. Cabrera CS et al. SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting β2-agonist use in asthma. Eur Respir J. 2020 Feb 12; 55(2): 1901858.
We hope that you found the content valuable. To ensure that we continue to provide topics and content of interest, we would very much value your feedback by completing a short questionnaire.
Professor Jenni Quint
Consultant Respiratory Physician & Clinical Senior Lecturer